Recombinant Cynomolgus PDGF R beta/CD140b Protein, Active
Beta LifeScience
SKU/CAT #: BLK-01094P-100UG

Cynomolgus PDGF R beta on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Cynomolgus PDGF R beta/CD140b Protein, Active
Beta LifeScience
SKU/CAT #: BLK-01094P-100UG
Collections: All products, High-quality recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Cynomolgus PDGF R beta/CD140b Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Leu33-Lys531. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | A0A2K5TUS0 |
Target Symbol | PDGF R beta/CD140b |
Species | Cynomolgus |
Expression System | HEK293 |
Tag | C-His |
Expression Range | Leu33-Lys531 |
Mol. Weight | The protein has a predicted MW of 57.49 kDa. Due to glycosylation, the protein migrates to 75-105 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Activity | Immobilized Cynomolgus PDGFR beta, His Tag at 1ug/ml (100ul/well) on the plate. Dose response curve for Anti-PDGFRB Antibody, hFc Tag with the EC50 of 8.3ng/ml determined by ELISA. Contact us for detailed testing images. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | Platelet-derived growth factor receptor (PDGFR) signaling is involved in proliferation and survival in a wide array of cell types.PDGFR-β signalling, via TGF-β signalling, may be crucial for restoration of BBB integrity after cerebral ischemia and therefore represents a novel potential therapeutic target. |